+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer

Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer

Breast 14(5): 368-374

Fifty-seven patients with metastatic breast cancer have been treated with reduced dose capecitabine 1g/m2 twice daily for 14 days repeated every 3 weeks after failure of a number of chemotherapy regimens or hormonal treatment. The overall objective response rate was 28% with 2% complete response rate and 26% partial response. Twenty nine percent objective response rate was achieved in 17 patients pretreated with anthracyclines and taxanes. The median duration of response and survival were 8.5 and 9 months, respectively. One and two year overall survival probabilities were 37% and 20%, respectively. The most common treatment-related adverse events (all grades) were hand-foot syndrome (HFS) (32%), nausea (21%) and diarrhoea (19%). Dose limiting toxicities, especially HFS were rare. Within the limits of phase II trial, this reduced dose of capecitabine appears as effective for advanced breast cancer as full dose capecitabine with a lower incidence of toxicity.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 012492087

Download citation: RISBibTeXText

PMID: 16216738

DOI: 10.1016/j.breast.2004.12.005

Related references

Capecitabine An active and well tolerated treatment option for patients with metastatic breast cancer recurring after taxane-containing chemotherapy Results of a multicenter phase II trial. Breast Cancer Research & Treatment 64(1): 83, 2000

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Annals of Oncology 16(8): 1289-1296, 2005

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Clinical Breast Cancer 8(2): 162-167, 2008

Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. Journal of Clinical Oncology 9(10): 1731-1735, 1991

Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer. Journal of Nippon Medical School 83(2): 81-86, 2016

Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?. Breast 19(5): 377-381, 2010

Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. ChemoTherapy 54(5): 352-356, 2008

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters 10(4): 2598-2602, 2015

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters 9(2): 987-993, 2015

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11(4): 325-335, 2006

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. Journal of Clinical Oncology 31(23): 2870-2878, 2013

High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. EJC Suppl.s 1(5): S270, 2003

A multicentric phase II study with vinorelbine and protracted fluorouracil infusion for advanced breast cancer patients previously treated with anthracyclines and/or taxanes Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated?. European Journal of Cancer 38(Suppl. 3): S70, 2002

Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clinical Breast Cancer 6(6): 518-524, 2006